We focus on “hard targets” in cancer and autoimmune disease with strong biological validation that have not been successfully drugged
We deploy our proprietary Rational Antibody Discovery platform to discover and engineer precision therapies, unlocking the therapeutic potential of these targets
Pipeline & Partners
Hummingbird Bioscience to Speak at 2021 Virtual Symposium: “VISTA: A New Immune...
15 June 2021